Skip to content
Menu
Home
About Us
Life Wins
Chairman’s Profile
Board Of Directors
Team Wockhardt
Corporate Milestones
Research & Development
R&D at Wockhardt
New Drug Discovery
Pipeline / Projects
News & Events
Publications
WCK 5222
WCK 4873
WCK 4282
WCK 6777
Biologicals
News & Events
Pipeline / Projects
Publications
R&D Contact
Our Business Verticals
Our Manufacturing Units
Global Footprint
India
UK & Europe
US
Emerging Markets
Products
India Branded Business
Trademark Products
Quality
Digital Footprint
Awards & Recognitions
Investors
From Chairman’s Office
AGM Speech
Letter to Shareowners
Financials
Financials at a Glance
Annual Report
Quarterly Results
Financial Press Releases
Related Party Transactions
Subsidiary Financials
Annual Return
Corporate Governance
Policies & Codes
Committee’s of the Board
Familiarisation programs
Shareholding Pattern
Secretarial Compliance Report
Authorised KMP
Corporate Actions
Announcements / Disclosures
Shareholders Meeting/ Postal ballot
AGM Notice
Proceedings
IEPF
Unclaimed Dividend
Nodal Officer
Analyst/ Investors
Presentation
Audio / Video Recording
Transcript
Shareowner Services
FAQ
Green Initiative
Investor Contact
Stock Quotes
Credit Rating
careers
Introduction
Life@Wockhardt
L&D Initiatives
Voice of Wockhardians
The Wockhardian
Career@Wockhardt
Media
Press Release
Media Coverage
Video Coverage
Media Kit
Sustainability
Contact us
Home
/
2022-2023
/
Page 2
PDF Year:
2022-2023
Home
Wockhardt’s Q3 FY23 EBITDA growth @37% over Q2 FY23
Intimation of the Meeting of Board of Directors – 13 Feb 2023
FINANCIAL RESULTS FY23 Q3
WOCKHARDT’S Q3 FY23 EBITDA GROWTH @37% OVER Q2 FY23
Shareholding Pattern for the quarter ended 31 December 2022
Credit Rating Intimataion India Ratings 21.12.2022
Chairman’s Letter to Shareowners Q2 FY22 – 23
Board Meeting Intimation – 04 – 11 – 2022
WOCKHARDT’S Q2 FY23 TOPLINE GROWTH @14% AND EBITDA GROWTH @369% OVER PREVIOUS QUARTER
FINANCIAL RESULTS FY23 Q2
Posts navigation
Previous page
Page
1
Page
2
Page
3
…
Page
5
Next page
